ACCOUNTS - Final Accounts preparation

Auditor's remuneration

During the year, the Company obtained the following services from the Company's auditor:

Registered number: SC479923

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

COMPANY INFORMATION

Directors	Jason Alan Elder (appointed 27 February 2026)
	Joyce Lean Lunsford (appointed 27 February 2026)
	Gregory Alan Molter (appointed 27 February 2026)
	Tony Taylor


Registered number	SC479923


Registered office	Holm Street
	Strathaven
	Lanarkshire
	ML10 6NB


Independent auditor	AAB Audit & Accountancy Limited
	133 Finnieston Street
	Glasgow
	G3 8HB

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

CONTENTS

	Page
Strategic report	1
Directors' report	2 - 3
Directors' responsibilities statement	4
Independent auditor's report	5 - 8
Statement of comprehensive income	9
Statement of financial position	10
Statement of changes in equity	11
Notes to the financial statements	12 - 17

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

STRATEGIC REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

Introduction

The principal activity of the Company is that of an intermediate holding company.

Business review

Refer to the results and dividends section of the Directors’ report.

Principal risks and uncertainties

While risk cannot be eliminated altogether, actions are taken to mitigate risk wherever possible. As a matter of policy, the Company does not enter into speculative activities. The material business and operational risks that the Directors consider the Company to be exposed to are:

Risk	Mitigating factor
Liquidity and cashflow The Company is exposed to a range of financial risks, both internally and externally driven, such as trade and intercompany non repayment of debt or fluctuation in foreign exchange rates.	In order to ensure that sufficient funds are available to fund ongoing operations and future developments, management regularly reviews the cash flow forecasts and financing arrangements of the business to ensure that there is sufficient funding in place. This includes reviews of the cash flow forecasts and operational performance of the entities from which the intercompany debt is due to monitor recoverability issues or the presence of indicators of impairment.
Operational performance of the companies from which balances are recoverable	Management regularly reviews the cash flow forecasts and operational performance of the companies in which the receivables are held to ensure that no recoverability issues or indicators of impairment are present. Management accounts for any recoverability issues or impairment identified appropriately where or if applicable.

In accordance with its risk management guidelines the Company raises awareness of business risks at all operational management levels and encourages all management teams to assess and manage risk appropriately. The Company ensures that appropriate insurance cover is in place for the Company in respect of the customarily insured liabilities and claims. The risks are monitored by the Directors on a regular basis.

Key performance indicators

No specific key performance indicators are monitored as this is a holding company only.

This report was approved by the board and signed on its behalf.

Tony Taylor

Director

Date: 4 September 2026

Page 1

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

DIRECTORS' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

The directors present their report and the financial statements for the year ended 31 December 2025.

Results and dividends

The profit for the year, after taxation, amounted to £4,642,916 (2024 - £10,510,253).

A divisional reorganisation took place during the year ended 31 December 2025 and 31 December 2024. The Company paid a cash dividend of £1,610,674 (2024: £896,883) and a dividend in specie of £nil (2024: £5,422,732) to its immediate parent, LCP Bidco Limited.

Directors

The directors who served during the year were:

Tony Taylor

Claire Rose Collins (resigned 26 March 2025)

Gail Louise Hunter (appointed 20 March 2025, resigned 27 February 2026)

Political contributions

The Company made no political donations and incurred no political expenditure during the year (2024: £nil).

Going concern

The Company’s business activities, together with factors likely to affect its future development, performance and position are considered by the Directors on an annual basis.

The Directors have, at the time of approving the financial statements, a reasonable expectation that the Company has the adequate resources for the Company to continue to adopt the going concern basis of accounting in preparing these financial statements. Further detail is contained in the statement on going concern within note 2.3 to the financial statements.

Future developments

The Directors are not aware, at the date of this report, of any likely major changes in the Company's activities.

Directors’ insurance and indemnities

As permitted by the Companies Act 2006, the Company purchases and maintains directors’ and officers’ insurance cover against certain legal liabilities and costs incurred by the Directors and Officers of the Company, in the performance of their duties. The Company has also granted an indemnity to each of its directors in relation to the Directors’ exercise of their powers, duties and responsibilities as directors of the Company, the terms of which are in the Companies Act 2006.

Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:

∙so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and

∙the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Page 2

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

DIRECTORS' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2025

Post balance sheet events

On 27 February 2026, the share capital of LCP Bidco Limited (this Company’s immediate parent) was sold by Element to AAG GB Inc, a subsidiary of Alchemy Analytical Group LLC, based in Michigan. In the opinion of the Directors of the Company, this is not likely to significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company.

Auditor

The auditor, AAB Audit & Accountancy Limited, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board and signed on its behalf.

Tony Taylor

Director

Date: 4 September 2026

Page 3

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

DIRECTORS' RESPONSIBILITIES STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2025

The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the directors are required to:

∙select suitable accounting policies for the Company's financial statements and then apply them consistently;

∙make judgements and accounting estimates that are reasonable and prudent;

∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Page 4

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CRAWFORD SCIENTIFIC HOLDINGS LIMITED

Opinion

We have audited the financial statements of Crawford Scientific Holdings Limited (the 'Company') for the year ended 31 December 2025, which comprise the Statement of comprehensive income, the Statement of financial position, the Statement of changes in equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

∙give a true and fair view of the state of the Company's affairs as at 31 December 2025 and of its profit for the year then ended;

∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

∙have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Page 5

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CRAWFORD SCIENTIFIC HOLDINGS LIMITED (CONTINUED)

Other information

The other information comprises the information included in the Annual Report other than the financial statements and our Auditor's report thereon. The directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

∙the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

∙the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

∙the financial statements are not in agreement with the accounting records and returns; or

∙certain disclosures of directors' remuneration specified by law are not made; or

∙we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Directors' responsibilities statement set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Page 6

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CRAWFORD SCIENTIFIC HOLDINGS LIMITED (CONTINUED)

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We obtained an understanding of the legal and regulatory frameworks within which the company operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006 and Taxation legislation.

We identified the greatest risk of material impact on the financial statements from irregularities including fraud to be:

∙Management override of controls to manipulate the company’s key performance indicators to meet targets;

∙Management judgement applied in calculating estimates and provisions; and

∙Compliance with relevant laws and regulations which directly impact the financial statements and those that the company needs to comply with for the purpose of trading.

Our audit procedures to respond to these risks included:

∙Testing of journal entries and other adjustments for appropriateness;

∙Evaluating the business rationale of significant transactions outside the normal course of business;

∙Reviewing judgements made by management in their calculation of accounting estimates for potential management bias;

∙Enquiries of management about litigation and claims and inspection of relevant correspondence;

∙Reviewing legal and professional fees to identify indications of actual or potential litigation, claims and any non-compliance with laws and regulations;

∙Performing a disclosure checklist on the financial statements to ensure Companies Act 2006 requirements are satisfied;

∙Analytical procedures to identify any unusual or unexpected trends or relationship; and

∙Reviewing minutes of meetings of those charged with governance to identify any matters indicating actual or potential fraud.

Page 7

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CRAWFORD SCIENTIFIC HOLDINGS LIMITED (CONTINUED)

Auditor's responsibilities for the audit of the financial statements (continued)

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.

Other matters

In the previous accounting year the directors of the Company took advantage of audit exemption under S479 of the Companies Act 2006. Therefore the prior year financial statements (31 December 2024) were unaudited.

Use of our report

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Stuart Rose (Senior statutory auditor)

for and on behalf of

AAB Audit & Accountancy Limited

Statutory Auditor

133 Finnieston Street

Glasgow

G3 8HB

4 September 2026

Page 8

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2025

	2025	2024
Note	£	£


Administrative expenses		-	(900)
Operating (loss)		-	(900)
Dividends received	6	4,642,916	10,512,997
Profit before tax		4,642,916	10,512,097
Tax on profit	7	-	(1,844)
Profit for the financial year		4,642,916	10,510,253

Other comprehensive income for the year
Total comprehensive income for the year		4,642,916	10,510,253

The notes on pages 12 to 17 form part of these financial statements.

Page 9

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

REGISTERED NUMBER: SC479923

STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2025

		2025		2024
Note		£		£

Fixed assets
Investments	8		8,649,249		8,649,249
Current assets
Debtors: amounts falling due within one year	9	-		36,468
		-		36,468
Creditors: amounts falling due within one year	10	-		(3,068,710)
Net current (liabilities)			-		(3,032,242)
Net assets			8,649,249		5,617,007

Capital and reserves
Called up share capital		433,319	433,319
Share premium account	11	1,689,398	1,689,398
Capital redemption reserve	11	16,000	16,000
Profit and loss account	11	6,510,532	3,478,290
		8,649,249	5,617,007

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

Tony Taylor

Director

Date: 4 September 2026

The notes on pages 12 to 17 form part of these financial statements.

Page 10

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2025

	Called up share capital	Share premium account	Capital redemption reserve	Profit and loss account	Total equity
	£	£	£	£	£
At 1 January 2024	433,319	1,689,398	16,000	(712,348)	1,426,369

Profit for the year	-	-	-	10,510,253	10,510,253
Dividends paid	-	-	-	(6,319,615)	(6,319,615)

At 1 January 2025	433,319	1,689,398	16,000	3,478,290	5,617,007

Profit for the year	-	-	-	4,642,916	4,642,916
Dividends paid	-	-	-	(1,610,674)	(1,610,674)
At 31 December 2025	433,319	1,689,398	16,000	6,510,532	8,649,249

The notes on pages 12 to 17 form part of these financial statements.

Page 11

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1.	General information

Crawford Scientific Holdings Limited (the ‘Company’) is a private limited company incorporated in Scotland. The Company is domiciled in the United Kingdom (UK) and its registered office is Holm Street, Strathaven, Lanarkshire, Scotland, ML10 6NB.

The principal activity of the Company is that of an intermediary holding company.

2.Accounting policies

2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

∙the requirements of Section 7 Statement of Cash Flows;

∙the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);

∙the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);

∙the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;

∙the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of EM Midco2 Limited as at 31 December 2025 and these financial statements may be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ, United Kingdom.

2.3

Going concern

The Company’s business activities, together with factors likely to affect its future development, performance and position, are considered by the Directors on an annual basis. The Company is a holding company and, as such, has limited direct obligations, with any significant liabilities generally being met by other group undertakings.

The Directors have, at the time of approving the financial statements, a reasonable expectation that the Company has the adequate resources for the Company to continue to adopt the going concern basis of accounting in preparing these financial statements.

Page 12

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

2.4

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:

∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and

∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

2.6

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 13

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.9

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

3.	Judgements in applying accounting policies and key sources of estimation uncertainty

The preparation of financial statements, requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the Balance sheet date and the amounts reported during the year for revenue and costs. However, the nature of estimation means that actual outcomes could differ from those estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The following judgements and estimates have had the most significant impact on amounts recognised in the financial statements.

Impairment of investments in subsidiaries

Critical judgement is applied when determining whether there are indicators of impairment in relation to investments in subsidiaries. In making this judgement the directors have considered internal and external factors impacting the investments’ market value and whether the net assets value of each investment is higher than the carrying value of the investment.

Fees payable to the Company's auditor for the audit of the Company's financial statements

3,000

Employees

	The Company has no employees other than the directors, who did not receive any remuneration (2024 - £NIL).
	The directors who served during the year are also directors of other group companies and do not consider it possible to identify the proportion of their remuneration relating to their roles as directors of this company.

Page 14

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

6.	Dividends received
		2025	2024
		£	£

	Dividends received	4,642,916	10,512,997

Deferred tax
Adjustment in respect of prior periods	-	1,844
Total deferred tax	-	1,844


	Tax on profit	-	1,844

Profit on ordinary activities before tax

4,642,916

10,512,097

Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2024 - 25%)	1,160,729	2,628,024
Effects of:
Expenses not deductible in determining taxable profit	-	225
Adjustments to tax charge in respect of prior periods	-	1,844
Exempt ABGH distributions	(1,160,729)	(2,628,249)
Total tax charge for the year	-	1,844

Page 15

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

8.	Fixed asset investments

		Investments in subsidiary companies
		£
	Cost or valuation
	At 1 January 2025	8,649,249
	At 31 December 2025	8,649,249

Subsidiary undertaking
The following was a subsidiary undertaking of the Company:
Name	Registered office	Principal activity	Class of shares	Holding

Crawford Scientific (UK) Ltd. (formerly Element Materials Technology Laboratory Solutions UK Limited)

Holm Street, Strathaven, Lanarkshire, ML10 6NB

Supply of scientific
products and technical
support services
including contract
analytical services
and consultancy

Ordinary

100%

Debtors

					2025	2024
					£	£


Amounts owed by group undertakings	-	36,468
	-	36,468

Amounts owed by group undertakings are unsecured, interest free, have no fixed repayment date and are repayable upon demand.

10.	Creditors: Amounts falling due within one year
		2025	2024
		£	£

Amounts owed to group undertakings	-	3,068,710
	-	3,068,710

Amounts owed by group undertakings are unsecured, interest free, have no fixed repayment date and are repayable upon demand.

Page 16

CRAWFORD SCIENTIFIC HOLDINGS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

11.

Reserves

Share premium account

Share premium is the amount by which the fair value of the consideration received exceeds the nominal value of the shares issued.

Capital redemption reserve

The capital redemption reserve is used to maintain the level of permanent capital where the company has bought back and cancelled its own shares.

Profit and loss account

The profit and loss account reserve comprises accumulated trading profits and losses.

12.

Related party transactions

The Company has taken advantage of the exemption as a subsidiary undertaking from disclosing transactions between wholly owned subsidiaries within the group, as allowed under FRS 102 section 33, ‘Related Party Transactions’.

The Directors are considered to be key management personnel of the Company. No other employees are considered to have authority or responsibility for planning, directing and controlling the activities of the Company.

There were no other related party transactions in the year (2024: £nil).

13.	Post balance sheet events

14.	Controlling party

At the balance sheet date the Company’s ultimate parent undertaking is Temasek Holdings (Private) Limited, a company incorporated in Singapore. The Company’s immediate parent is LCP Bidco Limited, registered in England and Wales.

The parent company of the smallest group of which the Company is a member, and for which group financial statements are prepared, is EM Midco2 Limited, a company incorporated in England and Wales.

The parent undertaking of the largest Group of which the Company is a member and for which group financial statements are prepared is Temasek Holdings (Private) Limited, a company incorporated in Singapore.

Copies of the Group financial statements of EM Midco2 Limited are available from Companies House, Crown Way, Cardiff, CF14 3UZ, United Kingdom. EM Midco2 Limited’s registered office is 3rd Floor Davidson Building, 5 Southampton Street, London, United Kingdom, WC2E 7HA.

Subsequent to the balance sheet date, the ultimate controlling party of the Company became Alchemy Analytical Group LLC following a sale of the share capital. This transaction is disclosed as a post balance sheet event in note 13.

Page 17